Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

[Oxidative stress after anthracycline therapy in patients with solid tumors].

Kocik M, Zimovjanova M, Petruzelka L, Kodydkova J, Vavrova L, Zak A.

Cas Lek Cesk. 2012;151(10):463-7. Czech.

PMID:
23256630
2.

Role of anthracyclines in the era of targeted therapy.

Cortés-Funes H, Coronado C.

Cardiovasc Toxicol. 2007;7(2):56-60. Review.

PMID:
17652804
3.

N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.

Ekstein S, Nir A, Rein AJ, Perles Z, Bar-Oz B, Salpeter L, Algur N, Weintraub M.

J Pediatr Hematol Oncol. 2007 Jul;29(7):440-4.

PMID:
17609620
4.

Cardiac toxicity after anthracycline chemotherapy in childhood.

Iarussi D, Indolfi P, Galderisi M, Bossone E.

Herz. 2000 Nov;25(7):676-88. Review.

PMID:
11141677
5.

Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.

Pinarli FG, Oğuz A, Tunaoğlu FS, Karadeniz C, Gökçora N, Elbeg S.

Pediatr Blood Cancer. 2005 Apr;44(4):370-7.

PMID:
15602715
6.

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.

Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V.

Pharmacol Rep. 2009 Jan-Feb;61(1):154-71. Review.

7.
8.

Anthracycline cardiotoxicity.

Jones RL, Swanton C, Ewer MS.

Expert Opin Drug Saf. 2006 Nov;5(6):791-809. Review.

PMID:
17044806
9.

Tumor and non-tumor tissues differential oxidative stress response to supplemental DHA and chemotherapy in rats.

Hajjaji N, Besson P, Bougnoux P.

Cancer Chemother Pharmacol. 2012 Jul;70(1):17-23. doi: 10.1007/s00280-012-1884-0. Epub 2012 May 18.

PMID:
22610354
10.

Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.

Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A.

Health Technol Assess. 2007 Jul;11(27):iii, ix-x, 1-84. Review.

11.

[Value of cardiac troponin I measurement in prediction of anthracycline-induced cardiotoxicity in breast cancer patients].

Huang WB, Yao GY, Liu MF, Chen RT, Chen LJ, Dong JY, Gu F, Guo ZZ, Ye CS.

Nan Fang Yi Ke Da Xue Xue Bao. 2011 Jun;31(6):1047-50. Chinese.

12.

B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.

Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L'Ecuyer T.

Pediatr Blood Cancer. 2007 Nov;49(6):812-6.

13.

Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.

Jirkovsky E, Popelová O, Kriváková-Stanková P, Vávrová A, Hroch M, Hasková P, Brcáková-Dolezelová E, Micuda S, Adamcová M, Simůnek T, Cervinková Z, Gersl V, Sterba M.

J Pharmacol Exp Ther. 2012 Nov;343(2):468-78. doi: 10.1124/jpet.112.198358. Epub 2012 Aug 22.

14.

Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.

Conklin KA.

Integr Cancer Ther. 2005 Jun;4(2):110-30. Review.

PMID:
15911925
15.

Assessment of anthracycline-induced cardiotoxicity with biochemical markers.

Horacek JM, Pudil R, Jebavy L, Tichy M, Zak P, Maly J.

Exp Oncol. 2007 Dec;29(4):309-13.

PMID:
18199989
16.

Genotyping the risk of anthracycline-induced cardiotoxicity.

Deng S, Wojnowski L.

Cardiovasc Toxicol. 2007;7(2):129-34. Review.

PMID:
17652817
17.

Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.

Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, Hogarty AN, Cohen MI, Barber G, Rutkowsky M, Kimball TR, Delaat C, Steinherz LJ, Zhao H, Tartaglione MR.

Am Heart J. 2001 Oct;142(4):577-85.

PMID:
11579345
18.

Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.

van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC.

Eur J Cancer. 2006 Dec;42(18):3191-8. Epub 2006 Sep 20.

PMID:
16987655
19.

An introduction to the metabolic determinants of anthracycline cardiotoxicity.

Menna P, Recalcati S, Cairo G, Minotti G.

Cardiovasc Toxicol. 2007;7(2):80-5. Review.

PMID:
17652809
20.

Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms.

Cascales A, Pastor-Quirante F, Sánchez-Vega B, Luengo-Gil G, Corral J, Ortuño-Pacheco G, Vicente V, de la Peña FA.

Oncologist. 2013;18(4):446-53. doi: 10.1634/theoncologist.2012-0239. Epub 2013 Apr 10.

Supplemental Content

Support Center